Piper Sandler Upgrades Design Therapeutics to Overweight, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi upgraded Design Therapeutics (NASDAQ:DSGN) from Neutral to Overweight and increased the price target from $6 to $12.
May 07, 2024 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Design Therapeutics was upgraded by Piper Sandler from Neutral to Overweight with a price target increase from $6 to $12.
The upgrade from Neutral to Overweight by a reputable analyst at Piper Sandler, along with a significant increase in the price target, suggests a strong bullish outlook for Design Therapeutics. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100